New Abecma KarMMa-9 Trial for Newly Diagnosed MM Patients

On Wednesday, September 7, 2seventy bio announced (press release) plans to initiate the KarMMa-9 study evaluating Abecma (BMS / 2seventy’s BCMA CAR-T) in newly diagnosed MM patients who have suboptimal response to transplant. The Celltelligence team will conduct an in-depth analysis of the KarMMa-9 trial as more details are released on CT.gov.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.